

Putnam BioRevolution ETF (SYNB)

Thematic | Factsheet as of June 30, 2025

Investment Overview

The fund seeks long term capital appreciation. The fund invests mainly in common stocks (growth or value stocks or both) of companies worldwide of any size with a focus on "biology revolution" companies.

Total Returns (%)

	Cumulative		Average Annual				Inception	
	3-Mth	YTD	1-Yr	3-Yr	5-Yr	10-Yr	Inception	Date
Market Price Return	1.27	-4.19	-8.55	—	—	—	4.95	9/29/2022
NAV Returns	1.23	-4.34	-8.51	—	—	—	4.95	9/29/2022
Benchmark	10.94	6.20	15.16	—	—	—	23.21	—

Calendar Year Total Returns (%)

	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Market Price Return	2.33	12.13	—	—	—	—	—	—	—	—
NAV Returns	2.47	12.25	—	—	—	—	—	—	—	—
Benchmark	25.02	26.29	—	—	—	—	—	—	—	—

Performance data quoted represents past performance, which does not guarantee future results. Current performance may be lower or higher than the figures shown. Principal value and investment returns will fluctuate, and investors' shares, when redeemed, may be worth more or less than the original cost. Performance would have been lower if fees had not been waived in various periods. Total returns assume the reinvestment of all distributions and the deduction of all fund expenses. An investor cannot invest directly in an index, and unmanaged index returns do not reflect any fees, expense or sales charges. Returns for periods of less than one year are not annualized. For current month-end performance, please visit franklintempleton.com.


Net Asset Value (NAV) returns are based on the NAV of the ETF; Market Price returns are based upon the official closing price of the ETF's shares. Returns are average annualized total returns, except for those periods of less than one year, which are cumulative. Market Price returns are calculated using the closing price as of 4 p.m. Eastern time on each trading day (when NAV is normally determined for most funds), and do not represent the returns you would receive if you traded shares at other times. Performance for the ETF and its benchmark index are as of the ETF's last trading day before the end of the period.

The total annual operating expenses are as of the fund's prospectus available at the time of publication. Actual expenses may be higher and may impact portfolio returns.

Growth of \$10,000

Inception through June 30, 2025

Market Price Returns, assuming dividends reinvested



The Growth of \$10,000 chart reflects a hypothetical \$10,000 investment on Market Price and assumes reinvestment of dividends and capital gains. Fund expense, including management fees and other expenses were deducted.

Fund Overview

Fund Inception Date	09/29/2022
Total Expense Ratio (%)	0.71
ETF Category	Active
Asset Class	Equity
Listed Exchange	NYSE Arca
NYSE Arca Ticker	SYNB
CUSIP	746729805
ISIN	US7467298052
Shares Outstanding	175,000

Benchmark(s)

S&P 500 Index

Fund Characteristics

	Fund
Total Net Assets	\$4.96 Million
Number of Issuers	34
Average Market Cap (Millions USD)	\$267,218
Price to Book	3.79x
Price to Earnings (12-Month Forward)	21.56x

Top Equity Issuers (% of Total)

	Fund
Thermo Fisher Scientific	7.20
Corteva	6.51
Novozymes	5.98
AbbVie	5.02
Bio-Rad Laboratories	4.95
Ascendis Pharma	4.41
NVIDIA	4.40
AstraZeneca	4.15
Eli Lilly	3.91
Cadence Design Systems	3.77

Sector Allocation (% of Total)

	Fund	Benchmark
Health Care	57.20	9.32
Materials	24.12	1.88
Information Technology	8.17	33.11
Consumer Staples	6.26	5.50
Consumer Discretionary	2.18	10.37
Communication Services	0.00	9.79
Financials	0.00	14.03
Industrials	0.00	8.58
Other	0.00	7.41
Cash & Other Net Assets	2.06	0.00

Market Cap Breakdown (% of Total) (USD)

	Fund
Less than \$1.7B	2.77
\$1.7B - \$6.3B	5.87
\$6.3B - \$36.6B	38.23
\$36.6B - \$155.9B	33.59
Over \$155.9B	17.48
Cash and other assets	2.06

Portfolio Management

	Years with Firm	Years of Experience
Will Rives, CFA	12	11

What should I know before investing?

All investments involve risks, including possible loss of principal. To the extent the portfolio invests in a **concentration of certain securities, regions or industries**, it is subject to increased volatility. **Small- and mid-cap stocks** involve greater risks and volatility than large-cap stocks. The **investment style** may become out of favor, which may have a negative impact on performance. The portfolio is **non-diversified** and may invest in a relatively small number of issuers, which may negatively impact the performance and result in greater fluctuation in value. **Active management** does not ensure gains or protect against market declines. The manager may consider **environmental, social and governance (ESG) criteria** in the research or investment process; however, ESG considerations may not be a determinative factor in security selection. In addition, the manager may not assess every investment for ESG criteria, and not every ESG factor may be identified or evaluated. These and other risks are discussed in the fund's prospectus.

Glossary

Weighted Average Market Capitalization: A determination of a company's value, calculated by multiplying the total number of company stock shares outstanding by the price per share. For a portfolio, the value represents a weighted average based on the stocks held. **Price to Book:** The price per share of a stock divided by its book value (i.e., net worth) per share. For a portfolio, the value represents a weighted average of the stocks it holds. **Price to Earnings (12-month Forward):** A measure of the price to earnings ratio for a stock using the forecasted earnings for the next 12 months. For a portfolio, the value represents a weighted average of the stocks it holds.

Important Information

ETFs and ETPs trade like stocks, fluctuate in market value and may trade at prices above or below the ETFs/ETPs net asset value. Brokerage commissions and ETF expenses will reduce returns.

ETF/ETP shares may be bought or sold throughout the day at their market price, not their Net Asset Value (NAV), on the exchange on which they are listed. Shares of ETFs/ETPs are tradable on secondary markets and may trade either at a premium or a discount to their NAV on the secondary market.

Canada: This content is intended only for Canadian institutional investors that qualify as "permitted clients" as defined in National Instrument 31-103 - Registration Requirements, Exemptions and Ongoing Registrant Obligations. U.S. securities laws generally limit a non-U.S. fund's purchase of a U.S. registered mutual fund or ETF/ETP (a "U.S. Fund") to no more than 3% of the U.S. Fund's voting stock. You should consult your legal counsel prior to investing in a U.S. Fund.

CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.

The **S&P 500 Index** features 500 leading U.S. publicly traded companies, with a primary emphasis on market capitalization. Source: © S&P Dow Jones Indices LLC. All rights reserved. Important data provider notices and terms available at www.franklintempletondatasources.com. All data is subject to change.

© 2025 Franklin Templeton. Franklin Distributors, LLC. Member FINRA/SIPC. Putnam Investments is a Franklin Templeton Company.

Before investing, carefully consider a fund's investment objectives, risks, charges and expenses. You can find this and other information in each prospectus, or summary prospectus, if available, at www.franklintempleton.com. Please read it carefully.